This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Metacrine, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$0.59 |
| 52 Week Low | US$0.30 |
| Beta | -0.74 |
| 1 Month Change | 3.82% |
| 3 Month Change | 1.60% |
| 1 Year Change | 23.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.06% |
Noticias y actualizaciones recientes
Recent updates
Equillium acquires Metacrine to extend cash runway through 2024
Sep 06Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform
Jun 14Metacrine completes enrollment in mid-stage NASH trial
Jun 02Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH
Jan 05What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?
Dec 16
Metacrine reports Q3 results
Nov 12Rentabilidad de los accionistas
| MTCR | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 1.1% | -2.5% | -3.2% |
| 1Y | 23.7% | -3.7% | 19.3% |
Rentabilidad vs. Industria: MTCR exceeded the US Biotechs industry which returned 13.8% over the past year.
Rentabilidad vs. Mercado: MTCR exceeded the US Market which returned 13.8% over the past year.
Volatilidad de los precios
| MTCR volatility | |
|---|---|
| MTCR Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MTCR has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: MTCR's weekly volatility (4%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 10 | Dave Maggio | www.metacrine.com |
Resumen de fundamentos de Metacrine, Inc.
| Estadísticas fundamentales de MTCR | |
|---|---|
| Capitalización bursátil | US$25.48m |
| Beneficios(TTM) | -US$38.19m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.7x
Ratio precio-beneficio (PE)¿Está MTCR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MTCR | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$19.49m |
| Beneficio bruto | -US$19.49m |
| Otros gastos | US$18.70m |
| Beneficios | -US$38.19m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.87 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 37.2% |
¿Cómo se ha desempeñado MTCR a largo plazo?
Ver rendimiento histórico y comparativa